Prevalence and patterns of comorbidities in psoriasis: a cross-sectional study from Bangladesh
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20250424Keywords:
Psoriasis, Co-morbidities, Chronic inflammatory disorderAbstract
Background: Psoriasis is a chronic inflammatory disorder marked by red, scaly patches on the skin, often causing itching. Psoriasis manifests in several forms, with plaque psoriasis being the most common. This condition affects the skin, nails, joints, and other systems, leading to significant comorbidities like cardiovascular and metabolic disorders. These comorbidities, seen in two-thirds of patients, highlight the systemic inflammatory nature of psoriasis. Understanding these associations is crucial for dermatologists to provide comprehensive care for affected individuals. The study aims to investigate the comorbidities associated with psoriasis.
Methods: This cross-sectional, observational study was conducted at the Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, including 120 adult psoriasis patients over one year. Ethical approval and informed consent were obtained.
Results: The most common age group was 41-50 years (30%), and the mean age of 43.63±13.69 years. Males comprised 60% of the population. Disease duration was up to 5 years for 80% of participants. Hypertension was the most frequent comorbidity (50%), followed by obesity (41.67%), dyslipidemia (33.33%), diabetes mellitus (25%), and metabolic syndrome (16.67%). Chronic plaque psoriasis was most prevalent (66.67%). Severity distribution indicated that 75% had mild/moderate psoriasis. Comparisons revealed no significant differences in comorbidities across psoriasis types or severity groups.
Conclusions: The study highlights the significant burden of comorbidities among psoriasis patients, particularly hypertension, obesity, dyslipidemia, diabetes mellitus, and metabolic syndrome. These conditions were prevalent regardless of psoriasis type or severity, underscoring the systemic nature of psoriasis and the need for comprehensive patient management.
Metrics
References
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Jo Am Acad Dermatol. 2008;58(5):826-50. DOI: https://doi.org/10.1016/j.jaad.2008.02.039
Naldi L. Epidemiology of psoriasis. Curr Drug Targets-Inflamm Allergy. 2004;3(2):121-8. DOI: https://doi.org/10.2174/1568010043343958
Tang MM, Chang CC, Chan LC, Heng A. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. Int J Dermatol. 2013;52(3):314-22. DOI: https://doi.org/10.1111/j.1365-4632.2011.05340.x
National Psoriasis Foundation. Psoriasis Statistics. Available at: https://www.psoriasis.org/content/ statistics. Accessed on 14 January 2024.
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633-6. DOI: https://doi.org/10.1111/j.1365-2133.2009.09593.x
Ali ME, Rahman GM, Akhtar N, Wahab MA, Rashid MM, Islam AZ. Efficacy and safety of leflunomide in the treatment of plaque type psoriasis. J Pak Assoc Dermatol. 2009;19(1):18-22.
Gudjonsson JE, Elder JT. Chapter 18. Psoriasis. Fitzpatrick’s dermatology in general medicine. McGraw-Hill Medical. 2012;8.
Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res. 2011;63(12):1729-35. DOI: https://doi.org/10.1002/acr.20627
Jama Y. Psoriasis patients had significant associations with co-morbid diseases. J Dermatol. 2013;50:15.
Mina AM, Tsen-Fang TS. Psoriasis and co-morbidity. Acta Dermato-Venereologica. 2020;100(3). DOI: https://doi.org/10.2340/00015555-3387
Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Therapy. 2010;23(2):114-8. DOI: https://doi.org/10.1111/j.1529-8019.2010.01304.x
Kudligi C, Odugouda SG, Kuntoji V, Bhagwat PV, Asati DP, Dhayaneethi E. A clinical study of psoriasis and its association with co-morbid conditions. J Pak Assoc Dermatol. 2016;26(4):298-305.
Ena PP, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiologica. 1985;40(2):199-205.
Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117. DOI: https://doi.org/10.3389/fphar.2020.00117
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21-8. DOI: https://doi.org/10.1016/j.clindermatol.2017.09.005
Rasool A, Priyanka MD, Kilaru KR, Paladugu R. Study of psoriasis and related co-morbid conditions. Int J Res. 2022;8(2):212. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20220366
Aftab S, Khan MA, Niaz F. Medical co-morbid conditions associated with psoriasis; psoriasis beyond skin. Prof Med J. 2020;27(03):511-6. DOI: https://doi.org/10.29309/TPMJ/2020.27.03.3302
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study. Br J Dermatol. 2007;157(1):68-73. DOI: https://doi.org/10.1111/j.1365-2133.2007.07986.x
Jarang T, Mogili P, Katakam BK, Netha GN. A Cross Sectional Study of Co-Morbidities Among Patients with Chronic Plaque Psoriasis at Tertiary Care Hospital. Neuro Quantol. 2022;20(7):3707.
Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895-902. DOI: https://doi.org/10.1111/j.1365-2133.2008.08707.x
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2007;298:321-8. DOI: https://doi.org/10.1007/s00403-006-0703-z
Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population‐based study. Br J Dermatol. 2008;159(6):1331-7. DOI: https://doi.org/10.1111/j.1365-2133.2008.08814.x
Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. JPMA. J Pak Assoc Dermatol. 2009;59(8):512-5.
Madanagobalane S, Anandan S. Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: a hospital-based case-control study. Indian J Dermatol. 2012;57(5):353-7. DOI: https://doi.org/10.4103/0019-5154.100474
Kutlu S, Ekmekci TR, Ucak S, Koslu A, Altuntas Y. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2011;77:193. DOI: https://doi.org/10.4103/0378-6323.77464
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-35. DOI: https://doi.org/10.1016/j.jaad.2006.08.040
Thomas J, Kumar NA, Manoharan D, Cynthia S, Prabu SS, Ahmed NA. A study of comorbid conditions in psoriasis. J Pak Assoc Dermatol. 2009;19(4):200-2.
Thomas J, Ashok Kumar N, Manoharan D, Ashwak Ahamed N. Co morbid conditions associated with psoriasis. J Indian Soc Teledermatol. 2010;4(1).
Kumar P, Thomas J. Comorbid conditions in psoriasis–Higher frequency in females: A prospective study. Indian Dermatol Online J. 2012;3(2):105-8. DOI: https://doi.org/10.4103/2229-5178.96701
Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775. DOI: https://doi.org/10.1016/j.amjmed.2011.03.028
Downloads
Published
How to Cite
Issue
Section
